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1 Abstract 
This is a randomized phase II double blinded trial aiming to evaluate the role of maintenance therapy 
with cabozantinib in High Grade Uterine Sarcomas (HGUtS) after stabilization or response to 
chemotherapy following surgery or in metastatic first line treatment. The main objective of the trial is 
to assess in High Grade Undifferentiated Uterine Sarcoma (HGUS), High Grade Endometrial Stromal 
Sarcoma (HGESS), High Grade Leiomyosarcomas (HGLMS) and High Grade (HG) adenosarcomas the 
efficacy (progression-free survival (PFS) at 4 months) of maintenance treatment with cabozantinib 
when compared with placebo after clinical benefit (CR, PR and SD) to standard chemotherapy 
(doxorubicin +/- ifosfamide) (given as an adjuvant treatment after curative surgery, or for locally 
advanced or metastatic disease). A cabozantinib/placebo dose of 60 mg daily is selected based upon 
results from preclinical and clinical studies. Protocol treatment is continued until completion (2 years) 
or occurrence of a withdrawal criterion. Patients randomized to the control arm can receive 
cabozantinib at the time of relapse, after unblinding of the study arm. A total of 54 patients 
randomized (1:1) to receive either cabozantinib monotherapy (experimental arm) or placebo (control 
arm) are needed to detect an increase from 50% to 80% PFS rate at 4 months. Recruitment started in 
February 2015, the trial has currently randomized 35 patients out of 83 registered. 
  
2 Introduction  
2.1 Background  
Uterine sarcomas are rare tumors that account for approximately 1% of female genital tract 
malignancies and 8% of uterine cancers, with an incidence of approximately 0.4 per 100,000 women 
(Ref. 40). Although the aggressive behavior of most cases is well recognized, their rarity and 
histopathological diversity has contributed to the lack of consensus on risk factors and optimal 
treatment and the outcome remains poor (Ref. 2). According to 2012 systematic review of data from 
1970 to 2011, leiomyosarcomas (LMS) is the most common subtype (63%), followed by endometrial 
stromal sarcoma (ESS) (21%) and less common subtypes as undifferentiated uterine sarcoma (Ref. 41). 
This study addresses high-grade entities that based on histopathology, clinical behavior and patient 
outcomes present similar high risk of recurrence and poor prognosis.  
On the basis of previous published data, it seems that undifferentiated sarcomas are positive for 
Platelet Derived Growth Factor Receptor (PDGFR)-a (Ref. 6), androgen receptor (AR) (Ref. 7), and WT1 
(Ref. 8). HGUS and high grade endometrial sarcoma (HGES) have very poor prognosis and most patients 
die of recurrent disease within two years of diagnosis. In a recent study (Ref. 10), the presence of 
vascular invasion was the only statistically significant prognostic factor, with a 5-year crude survival of 
83% and 17% when vascular invasion was absent or present, respectively (P=0.02). Local recurrences 
and distant metastases are associated with a high mortality. YWHAE-FAM22 ESS represent a clinically 
aggressive subtype of ESS classified as HGESS, and its distinction from the usual low-grade ESS with 
JAZF1 rearrangement and from HGUtS with no identifiable molecular aberration. In general, standard 
guidelines and decision-making protocols include adjuvant chemotherapy with anthracyclines +/- 
ifosfamide at adequate doses in patients with good performance status and poorly differentiated 
sarcoma with stage I and II or in patients with advanced disease (stage III/IV) (Ref. 11). In general, the 
median survival for metastatic HGUtS is less than 1 year. Typically, management of metastatic uterine 
sarcoma conforms to treatment practice for other metastatic soft tissue sarcomas (STS). The principles 
of management include surgical resection of isolated metastases, radiation to sites of local recurrence 
for disease control, and palliative systemic chemotherapy for advanced disease. No curative 
therapeutic option is currently available, with the possible exception of surgery for metastases isolated 
to the lung (Ref. 12). Systemic treatment for HGUS paralleled that for adult-type STSs, using 
doxorubicin +/- ifosfamide as single agents or in combination (Ref. 13). 
LMSs are the most common subtype of uterine sarcoma; most are high-grade malignancies with a high 
risk for recurrence and progression. Overall survival (OS) is dependent on stage, with 5-year survival 
estimates for stage I, 76%; stage II, 60%; stage III, 45%; and stage IV disease, 29% (Ref. 49). Uterine 
LMSs are staged using the International Federation of Gynecology and Obstetrics 2009 uterine 
sarcoma staging system, although anatomic staging systems perform poorly in survival prognostication 
(Ref. 50). Objective response rates can be achieved with systemic treatment for metastatic uterine 
LMS; in patients with symptomatic disease, chemotherapy may provide palliation of symptoms. There 
is no established superior first line chemotherapy regimen. Reasonable regimens to consider for first-
line therapy include doxorubicin, doxorubicin plus ifosfamide, gemcitabine, gemcitabine plus 
docetaxel with objective response observed between 17 and 36% of patients (Ref. 51, Ref. 52, Ref. 53, 
Ref. 54). Pazopanib 800 mg oral daily achieved objective response in about 6% of patients with 
metastatic STS in a phase III trial. The PFS was 20 weeks with pazopanib versus 7 weeks with placebo. 
There was no difference in OS (Ref. 55). This is currently the most frequently second line therapy for 
metastatic LMS after failure to CT including trabectedine. 
Adenosarcomas of the female genital tract are rare malignancies, originally described in the uterus, 
the most common site of origin, but they may also arise in extra uterine locations. Uterine 
adenosarcomas make up 5% of uterine sarcomas and tend to occur in postmenopausal women. 
Tumors that exhibit a high-grade sarcomatous overgrowth have a worse outcome. Extra uterine 
adenosarcomas also have a higher risk for recurrence. In view of their rarity, there have not been any 
clinical trials in adenosarcomas and relatively little research (Ref. 56). The management of patients 
with high grade metastatic adenosarcomas is similar to the management of patients with metastatic 
high grade sarcomas. It seems unlikely that there is an intrinsic difference between high grade 
sarcomas arising in adenosarcomas and their histological counterparts that arise de novo and a similar 
approach to management as in other sarcomas is reasonable.  
2.2 Rationale 
Due to the absence of effective treatments for HGUtS and the poor prognosis, new agents need to be 
investigated in these rare diseases.  
The vast majority of patients with metastatic soft-tissue and bone sarcomas have rapid disease 
progression and poor OS despite currently available palliative chemotherapy even with the best 
multimodality treatment. Although patients achieving clinical benefit with initial therapy may continue 
to receive chemotherapy until disease progression or unacceptable toxicity, chemotherapy can also be 
stopped after maximal benefit has been obtained with ongoing surveillance of metastatic disease until 
eventual disease progression. The benefits of continuing chemotherapy have never been proven to be 
greater than stopping therapy once benefit has been obtained, and there are known risks from 
cumulative drug-associated toxicities, such as cardiac toxicity associated with doxorubicin.  
An effective and convenient therapy that could be used to maintain benefits from prior cytotoxic 
chemotherapy, such as prolonged disease stability, might offer a useful addition to the pharmacologic 
management of sarcoma patients with metastatic disease. Angiogenesis plays an important role in the 
growth and dissemination of HGUtS and other STSs. High VEGF expression is an independent, poor 
prognostic factor for increased risk of metastases and decreased OS. (Ref. 15, Ref. 16, Ref. 17) 
 Anti-angiogenic therapeutics activity in STS 
Pazopanib (Votrient [GW786034]; GlaxoSmithKline) is an orally bioavailable, adenosine triphosphate-
competitive tyrosine kinase inhibitor of vascular endothelial growth-factor receptor (VEGFR)-1, -2, and 
-3, platelet-derived growth-factor receptor (PDGFR)-ɲ and  ?ɴ, and v-kit Hardy ?Zuckerman 4 feline 
sarcoma viral oncogene homolog (c-kit) that has activity in multiple cancers, including renal cell cancer, 
sarcomas, cervical and ovarian cancer. It is FDA-approved for the treatment of advanced renal-cell 
carcinoma and was approved for the treatment of patients with advanced STS who have received prior 
chemotherapy, excluding GIST and adipocytic STS (Ref. 19).  
Maki and his colleagues conducted a phase II multi arm study with single-agent sorafenib at a dose of 
400 mg twice daily in patients with advanced STS (Ref. 22). Although the response rates were lower 
with sorafenib in this study than standard cytotoxic agents, PFS for leiomyosarcoma and angiosarcoma 
patients was comparable, supporting the activity of sorafenib in these diagnoses. In comparison, 
imatinib was inactive in 16 angiosarcoma patients as part of a phase II study, supporting VEGF receptor 
blockade as the key mechanism of action of sorafenib in these histologies. 
Regorafenib, a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3, and tumor cell signaling kinases 
(RET, KIT, PDGFR, and Raf), was assessed in a randomized phase II in patients with metastatic STSs 
previously treated with anthracycline. Regorafenib is active in non-adipocytic soft tissue sarcomas. In 
the leiomyosarcoma cohort, progression-free survival was 3·7 months (95% CI 2·5-5·0) with 
regorafenib versus 1·8 (1·0-2·8) months with placebo (HR 0·46 [95% CI 0·46-0·80] p=0·0045). In the 
other sarcoma cohort (i.e. non-liposarcoma, leiomyosarcoma or synovial sarcoma), progression-free 
survival was 2·9 months (95% CI 1·0-7·8) with regorafenib versus 1·0 (0·9-1·9) with placebo (HR 0·46 
[95% CI 0·25-0·81] p=0·0061) (Ref. 60, Ref. 61).  
 Cabozantinib and its potential role 
VEGFR2 (vascular endothelial growth factor receptor 2), MET (hepatocyte growth factor [HGF] 
receptor), and RET (rearranged during transfection) all play important roles in cancer biology. Up 
regulation of MET is found in a wide range of malignancies ? including thyroid, prostate, ovarian, lung, 
and breast cancers ? and is associated with more aggressive and invasive phenotypes of cancer cells in 
vitro and metastases in vivo. MET-driven metastasis may be exacerbated by a number of factors, 
including tumor hypoxia caused by selective inhibition of the VEGF pathway or by androgen 
deprivation in the treatment of prostate cancer. Cabozantinib (XL184) inhibits the receptor tyrosine 
kinases VEGFR2, MET, AXL and RET. In vivo pharmacodynamic activity of cabozantinib against VEGFR2, 
MET, AXL and RET has been demonstrated in preclinical studies and has been associated with tumor 
growth inhibition and tumor regression. In preclinical studies, cabozantinib inhibited tumor 
angiogenesis, tumor invasiveness and metastasis, and the progression of tumors in bone compared to 
sunitinib. This activity on VEGFR2 and MET make a good rational to evaluate cabozantinib in cancer, as 
angiogenesis pathways are one of the drivers of tumor progression. 
Cabozantinib is supplied as both capsules and tablets, but the two formulations are not 
interchangeable. Cabozantinib capsules (140 mg) were approved by the FDA on 29 November 2012 for 
the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). On 21 March 
2014, cabozantinib capsules (140 mg) were approved by the European Commission for the treatment 
of adult patients with progressive, unresectable locally advanced or metastatic MTC (EXAM study). On 
25 April 2016, cabozantinib tablets (60 mg) were approved by FDA in patients with advanced RCC who 
have received prior anti-angiogenic therapy. Cabozantinib is commercially available as both capsules 
and tablets in the United States and is currently available only as capsules in the European Union. It is 
currently undergoing clinical trials in the following indications: STS, prostate cancer, ovarian cancer, 
glioblastoma, melanoma, breast cancer, non-small cell lung cancer, and hepatocellular cancer.  
Given the activity of cabozantinib in several malignancies and the activity of VEGF-targeting agents, 
such as pazopanib, sorafenib and sunitinib in STS, agents from the similar class could be explored in 
the management of patients in maintenance treatment after chemotherapy in HGUS, HGESS, HGLMS 
and HG adenosarcoma. In this context, and due to the anti-tumor activity, spectrum of action, 
cabozantinib is proposed as the novel therapy in this trial. The aims are to evaluate the therapeutic 
benefit of maintenance treatment with cabozantinib for patients with HGUS, HGESS, HGLMS and HG 
adenosarcoma who have achieved response (RECIST 1.1 CR or PR) or stable disease (RECIST 1.1 SD) to 
chemotherapy in first line treatment or at first metastatic relapse. 
2.3 International Rare Cancers Initiative 
The International Rare Cancers Initiative (IRCI) is a strategic collaboration between Cancer Research 
UK, the UK National Institute for Health Research Cancer Research Network (NCRN), the US National 
Cancer Institute (NCI), the European Organisation for Research and Treatment of Cancer (EORTC) and 
the French National Institute of CaŶĐĞƌ  ?/EĂ ? ? /Z/ ?ƐĂŝŵŝƐƚŽĨĂĐŝůŝƚĂƚĞƚŚĞĚĞǀĞůŽƉŵĞŶƚŽĨĐůŝŶŝĐĂů
trials for patients with rare cancers in order to improve outcomes. This trial was initiated by the EORTC 
internally as a collaboration between the EORTC Soft Tissue Bone Sarcoma Group (STBSG) and the 
EORTC Gynecological Cancer Group (GCG). Although the protocol was developed through the IRCI 
platform with input from all parties, ultimately only the NCRN group was able to join recruitment.  
3 Trial Design 
This is a randomized phase II double blinded trial aiming to evaluate the role of maintenance therapy 
with cabozantinib in HGUS, HGESS, HGLMS and HG adenosarcoma after stabilization or response to 
chemotherapy following surgery or in advanced first line treatment. In this trial, 54 patients will be 
randomized (1:1) to receive either cabozantinib monotherapy (experimental arm) or placebo (control 
arm).The activity of cabozantinib maintenance will be assessed by formal comparison of PFS at 4 
months to that of the control arm (placebo). To make the trial more attractive to patients and 
investigators, in the placebo arm cross-over to cabozantinib at progression is permitted. Due to this 
cross-over, the selected primary endpoint is PFS as it is unaffected by the potential cross-over effect. 
Overall survival and toxicity remain key secondary endpoints. 
The enrollment process is composed of two steps. Patient registration must take place between 4 
weeks before the start and no later than 4 weeks after the administration of the first dose of 1st line 
treatment. Written informed consent for collection of tissue blocks or slides and any other trial-specific 
procedures are obtained from the patient. This screening step is needed to allow for timely central 
histological review. Randomization is only allowed after pathological confirmation by central review 
and should occur no later than 12 weeks after last administration of 1st line treatment.  
Eligible patients will be randomized to receive either cabozantinib monotherapy or placebo. 
Cabozatinib will start between three and twelve weeks after the end of the doxorubicin based regimen 
(see Appendix A for allowed regimens and doses of doxorubicin +/- ifosfamide). Protocol treatment is 
continued until completion (2 years) or occurrence of a withdrawal criterion. These criteria are the 
occurrence of any of the following: disease progression, diagnosis of a second malignancy, patient 
refusal, excessive toxicity (impeding further protocol therapy), unblinding of the study treatment, 
pregnancy or failure to use adequate contraception.  
Patients discontinuing therapy in the absence of progression should not receive any other cancer 
treatment before their disease progresses, unless this is clearly not in the interest of the patient. After 
documented disease progression (according to RECIST 1.1; Ref 62), the treatment will be unblinded. 
Subjects receiving cabozantinib shall be treated at the investigator discretion. Subjects receiving 
placebo shall be offered the option of receiving cabozantinib up to further progression. This cross-over 
is not mandatory and at the investigator decision.  
4 Patient selection criteria 
The following eligibility criteria are mandatory and will be verified at the registration and 
randomization step respectively. 
4.1 At Registration 
x Patients who are suitable for treatment with doxorubicin +/- ifosfamide and fall within one of the 
following patient populations: 
x HGUS, HGESS, HGLMS and HG adenosarcoma  
x FIGO stage II and stage III : if adjuvant chemotherapy is proposed  
x FIGO stage IV: if first line chemotherapy is proposed  
The following tumor types are NOT eligible: low-grade ESS, leiomyosarcoma (low or intermediate 
grade), carcinosarcoma, low-grade adenosarcoma, rhabdomyosarcoma (alveolar or embryonal) and 
soft tissue PNET of uterus/cervix. 
See appendix B for FIGO staging of uterine sarcomas. 
x 1 formalin fixed paraffin embedded (FFPE) block of tumor tissue (if not available, at least 1 H/E 
(haematoxylin/eosin) and 15 unstained slides) is sent after registration of a patient. 
x Histological central review is mandatory to confirm histology and grade.  
x Patients must be at least 18 years old 
x Before patient registration, written informed consent for central collection of tissue blocks or 
slides and any other trial-specific procedures must be obtained from the patient according to 
ICH/GCP, and national/local regulations, allowing for collection, storage and analysis of tissue and 
screening procedures. 
4.2 At Randomization 
x Central pathological confirmation: Histological evidence of HGUS, HGESS, HGLMS and HG 
adenosarcoma. 
x Non-progressive patients (CR, PR, SD) after first line treatment (standard chemotherapy consisting 
of 4 to 6 cycles of doxorubicin alone or in combination with ifosfamide) and at time of 
randomization.  
x No contraindications to cabozantinib (e.g. no known immediate or delayed hypersensitivity 
reaction or idiosyncrasy to drugs chemically related to cabozantinib) 
x Patients able to swallow and retain oral tablets. 
x No planned use of chemotherapy, radiation therapy, radionuclide treatment, small molecule TKI 
or hormonal therapy, and any other investigational agent (Cabozantinib/placebo) during the 
treatment period. 
x No prior treatment with cabozantinib 
x WHO/ECOG performance status 0-2 
x ZĞĐŽǀĞƌǇ ƚŽ ďĂƐĞůŝŶĞŽƌA? Grade 1 CTCAE v.4.0 from toxicities related to any prior treatments, 
unless AE(s) are clinically non-significant and/or stable on supportive therapy 
x The subject has organ and marrow function and normal laboratory values before randomization  
x Clinically normal cardiac function based on the institutional LLN (LVEF assessed by MUGA or ECHO), 
normal 12 lead ECG (no prolongation of corrected QT interval (QTc) > 500 msecs according to 
Fridericia's formula) and no history of any one or more of the specific cardiovascular conditions 
within the past 6 months 
x No history of congenital long QT syndrome: For QTc interval > 500 msec within 1 month before the 
first dose of study treatment: three ECGs must be performed for eligibility determination. If the 
ĂǀĞƌĂŐĞŽĨƚŚĞƐĞƚŚƌĞĞĐŽŶƐĞĐƵƚŝǀĞƌĞƐƵůƚƐĨŽƌYdĐ&ŝƐA? ? ? ?ŵƐĞĐ ?ƚŚĞƉĂƚŝĞŶƚŵĞĞƚƐĞůŝŐŝďŝůŝƚǇŝŶ
this regard. 
x No concurrent severe, clinically relevant hypothyroidism or thyroid dysfunction within 7 days 
before the first dose of study treatment.  
x No patient with concurrent uncontrolled hypertension defined as sustained blood pressure (BP) 
> 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment within 
7 days of the first dose of study treatment; 
x No concomitant anticoagulation at therapeutic doses with oral anticoagulants (e.g., warfarin, 
direct thrombin and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel);  
x No patients who have suffered a cerebrovascular accident at any time in the past, patients who 
have suffered a transient ischemic attack in the past 6 months, patients who have suffered a deep 
venous thrombosis (DVT) or a pulmonary embolism in the past 6 months  
x No Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula 
formation. 
x No clinically-significant gastrointestinal bleeding within 6 months before the first dose of study 
treatment 
x No patients with evidence of tumor invading the GI tract (esophagus, stomach, small or large 
bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days 
before the first dose of study treatment (Cabozantinib/placebo). 
x No patients with radiographic evidence of cavitating pulmonary lesion(s). 
x No patients with tumor in contact with, invading or encasing any major blood vessels. 
x No evidence of active bleeding or bleeding diathesis.  
x EŽŚĞŵŽƉƚǇƐŝƐA? ? ? ?ƚĞĂƐƉŽŽŶ ? ? ? ?ŵů ?ŽĨƌĞĚďůŽŽĚǁŝƚŚŝŶ ?ŵŽŶƚŚƐďĞĨŽƌĞƚŚĞĨŝƌƐƚdose of study 
treatment. 
x No signs indicative of pulmonary hemorrhage within 3 months before the first dose of study 
treatment 
x No major surgery or trauma within 12 weeks prior to first dose of study drug and/or presence of 
any non-healing wound, fracture or ulcer. Complete wound healing from major surgery must have 
occurred one month before the first dose of study treatment.  
x Patients with clinically relevant ongoing complications from prior surgery are not eligible 
x No poor oral hygiene or invasive dental or orofacial procedures within 28 days before the first dose 
of study treatment. 
x No concurrent or planned treatment with strong inhibitors or inducers of cytochrome P450 3A4/5 
(a one week wash-out period is necessary for patients who are already on these treatments). 
x No other malignancies within 5 years prior to randomization, with the exception of those with a 
negligible risk of metastasis or death, treated with expected curative outcome (such as adequately 
treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, ductal carcinoma in situ 
treated surgically with curative intent, and non-muscle invasive urothelial cell carcinoma). 
x Women of child bearing potential (WOCBP) must have a negative serum/urine pregnancy test 
within 3 days prior to the first dose of study treatment. Females of childbearing potential are 
defined as premenopausal females capable of becoming pregnant (i.e., females who have had any 
evidence of menses in the past 12 months, with the exception of those who had prior 
hysterectomy). However, women who have been amenorrheic for 12 or more months are still 
considered to be of childbearing potential if the amenorrhea is possibly due to prior 
chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons. 
x Patients of childbearing / reproductive potential should use adequate birth control measures, as 
defined by the investigator, during the study treatment period and for at least 4 months after the 
last study treatment. 
x Female subjects who are breast feeding should discontinue nursing prior to the first dose of study 
treatment and until 8 weeks after the last study treatment. 
x Absence of any psychological, familial, sociological or geographical condition potentially 
hampering compliance with the study protocol and follow-up schedule; those conditions should 
be discussed with the patient before registration in the trial 
5 Objectives of the trial 
The main objective of the trial is to assess, in in HGUS, HGESS, HGLMS and HG adenosarcoma the 
activity of maintenance treatment with cabozantinib when compared with placebo after clinical 
benefit (CR, PR and SD) from standard chemotherapy (doxorubicin +/- ifosfamide) (given as an adjuvant 
treatment after curative surgery, or for locally advanced or metastatic disease) as measured by PFS at 
4 months. 
Secondary objectives include the efficacy of maintenance treatment with cabozantinib when 
compared with placebo using alternative endpoints namely: progression-free survival (PFS), overall 
survival (OS), response rate (RR), and duration of response among patients with measurable disease. 
Another secondary objective is to describe the safety profile of cabozantinib in patients with HGUS, 
HGESS, HGLMS and HG adenosarcoma (CTCAE 4.0). Exploratory objectives are to evaluate the 
response rate to doxorubicin-based chemotherapy for patients with measurable disease and to 
evaluate Health-Related Quality of Life (HRQoL) in each arm. 
 
6 Statistical considerations 
6.1 Statistical design 
This is a randomized phase II blinded trial aiming to randomize 54 patients equally over two arms to 
receive cabozantinib monotherapy (experimental arm) or placebo (control arm).  
The primary objective of the trial is to detect a difference of 30% in the primary endpoint, PFS rate at 
4 months, in favor of the experimental treatment arm. Due to the rarity of uterine sarcomas there are 
few randomized data to provide reliable outcome estimates. The evidence is mostly based on 
retrospective (small) series (Ref. 1). A review of survival data for endometrial and uterine sarcomas 
extracted from previous EORTC studies, revealed a median PFS of 4 months. As high grade ESS may be 
underrepresented in this dataset, we assume a PFS rate at 4 months for the control arm of 50-60%. A 
comparative phase II design as proposed by Korn et al (Ref. 32) is preferred over a non-comparative 
design due to the uncertainty in established reference outcomes inherent to rare cancer populations. 
The result is a comparative phase III trial design with increased error rates. Using a 1-sided Fisher exact 
test, stratified by adjuvant versus metastatic disease and response at end of chemotherapy, at a level 
of significance of 15% (alpha), a total of 54 patients are needed to detect an increase from 50% to 80% 
with 85% power. With these design characteristics, but assuming PFS rate at 4 months for the control 
arm of 60%, an improvement of 28% (i.e. from 60% to 88%) could be detected. In order to randomize 
the required 54 patients, a total of 90 patients are expected to be registered. This sample of 54 
randomized patients should yield an expected total of 35 PFS events at the time of final analysis. This 
would allow to detect a HR=0.49 with a 1-sided test at 15% significance level with 85% power. 
A minimization technique is used to randomize the patients between the two treatment arms, 
stratifying for collaborative group (EORTC vs NCRN), disease (adjuvant versus metastatic), response at 
end of first line chemotherapy (CR, PR vs SD) and operability (operable vs inoperable). Statistical 
analysis plan 
 
 
 Statistical methods 
The primary analysis will be performed according to the intent to treat principle: all randomized 
patients will be analyzed in the arm they were allocated by randomization. The superiority of the 
experimental arm against the control arm will be tested for PFS rate at 4 months using a 1-sided 
stratified Fisher exact test (Ref. 33) at the 15% significance level. The estimate of the 85% one-sided CI 
for the proportion of interest will be computed on the basis of the exact binomial distribution. The 
estimate of the difference between the binary proportions of the two treatment arms and the 
associated CI will be computed as well. 
Compliance tables to follow-up visits and to follow-up CT scans for assessment of progression (as PFS 
rate is the primary endpoint) will be produced. Compliance will be compared between arms using 
Fisher exact tests at each time point of assessment. High and similar compliance in both arms is 
required to avoid potential bias in the primary comparison. If a significant difference is found in the 
overall population, a preplanned subgroup analysis will be made in the adjuvant and metastatic 
subgroups respectively (closed testing procedure). The test in each subgroup will be performed on the 
primary endpoint as a Fisher exact test at 15% significance level. The type I error is not adjusted for 
multiple testing as this is an exploratory subgroup analysis. The homogeneity of the results in the two 
subgroups will not be formally tested.  
For the secondary endpoints (progression free survival, overall survival and response rate), no formal 
comparisons between arms will be performed. For time to event endpoints (PFS, OS and RR duration), 
curves will be estimated using the Kaplan-Meier technique (Ref. 34) by treatment arm. Hazard ratios 
and medians will be displayed with their 95% confidence interval. Response rates as per RECIST 
(version 1.1) will be displayed by treatment arm in each subgroup together with their 95% exact 
confidence interval.  
Safety data will be displayed by treatment arm in each subgroup for those patients who received at 
least one dose of the protocol treatment. The worst toxicity grade over all cycles according to the 
CTCAE criteria version 4.0 will be displayed by treatment arm.  
 Pre-planned sensitivity or exploratory analyses 
In case of high rate of drop-out, non-compliance with the tumor assessment schedule or non-
assessable progression status, a sensitivity analysis for the primary endpoint will be performed. The 
analysis will consider different methods for those patients with inadequate disease assessment at 4 
months. The PFS rate at 4 months will be estimated via Kaplan-Meier or interval censoring 
methodology. 
A preplanned subgroup analysis will be made in each of the histology subgroups (HGUS, HGESS, HGLMS 
and HG adenosarcoma).  
In order to assess the treatment effect of ifosfamide addition to doxorubicin during the screening 
phase, a preplanned comparative analysis is foreseen. Due to the lack of randomization, the ifosfamide 
addition is left to the discretion of the treating physician and will be influenced by subject and disease 
characteristics. As a result, baseline characteristics of treated subjects can differ systematically from 
those of subjects treated with monotherapy. In order to overcome such systematic differences when 
estimating the effect of ifosfamide on clinical outcomes, the subjects will be balanced via a propensity 
score, i.e. the probability of treatment assignment conditional on observed baseline characteristics. 
Conditional on an adequate propensity score, the distribution of observed baseline covariates will be 
similar between the two treatment groups: doxorubicin +/- ifosfamide treated patients. The outcomes 
of interest are response rate at end of the doxorubicin+/- ifosfamide treatment, progression-free 
survival and overall survival. All registered patients who received at least one cycle of doxorubicin+/- 
ifosfamide therapy will be included in this analysis. Assessment of the response rate will be limited to 
those patients with measurable disease. 
The available power to assess the response rate, progression-free survival and overall survival is 
difficult to estimate as the available sample size will depend on the number of patients registered in 
order to reach the 54 randomizations. Assuming 75 available patients and a response rate of 40%, the 
95% CI width for the response rate would be 2x6%. A total of 50 events would yield approx. 80% power 
to detect a HR=0.5 in either PFS or OS assuming a two-sided significance test at 10% and a 50%-50% 
split between groups of interest. 
6.2 Interim analyses 
No formal interim analysis for the activity endpoints is planned for this study. There was a formal 
evaluation of the adherence to the initial dose of 60 mg of cabozantinib. In the case of an unacceptable 
high proportion of dose reductions or termination, the initial dose would be set at 40 mg (with the 
possibility to re-escalate) for the remaining patients. A 30% or less rate of patients needing dose 
modification during the first two cycles will be considered acceptable; while a rate of 50% or more is 
considered as unacceptable. 
7 Discussion  
As of February 25th 2020, 11 out of 11 EORTC sites in 6 countries (BE, FR, DE, IT, NL, ES) and 7 out of 
11 UK sites have been activated for patient recruitment. A total of 82 patients have so far been 
registered, which is 91% of our target (90 patients). Of those, 35 patients were randomized out of a 
targeted total of 54 patients (64%).  
Recruitment is scheduled to end in 2020. Figure 2 shows the accrual registered and randomized 
patients: observed versus expected 
The screening failure rate is higher than anticipated. The assumption during the trial design was that 
only 40% of registered patient would not be eligible for randomization. In practice, this rate is closer 
to 55% (35 out of 79). The major reasons for non-randomization were a change in histological diagnosis 
by central review (15/44=34%) and progression during 1st line (14/44=32%) accounting for two thirds 
of the screening failures. Other reasons included patient decision, inadequate organ or marrow 
function or randomization > 12 weeks after 1st line. This highlights the importance of central review in 
rare cancers as 1 in 3 cases the histological diagnosis was changed. Unfortunately, the poor prognosis 
of these tumours adds substantial drop-out during the screening process. As planned per protocol, an 
evaluation of the adherence to the initial dose of 60 mg of cabozantinib was done to verify the 
feasibility of this starting dose. Based on two consecutive evaluations (June and October 2018), no 
concerns for pursuing the recruitment at the 60 mg dose were found and the trial continues with this 
initial dose as planned.  
We can also remark on the complexity of conducting clinical randomized trials in the field of rare 
cancers. This needs to be a priority not only for industry sponsored trials but also for academic groups  
The original concept of this trial was much more ambitious, enrolling HGUtS patients in the first line 
setting with subsequent follow-up for a maintenance study in patients who responded, and a 
randomization for patients who progressed during chemotherapy into a salvage treatment. This 
original trial design combined three objectives: improving response to 1st line chemotherapy, 
maintenance with anti-angiogenics and survival using a new compound at relapse. Such a platform 
trial would reduce time and costs compared to three separate studies. However, only industry support 
could only be provided for maintenance therapy; the other settings attracted no support. 
Randomization between two common regimens (doxorubicin alone versus doxorubicin + ifosfamide) 
was considered for the 1st line setting to add extra value to the overall trial but no consensus could be 
reached and this randomization was dropped to simplify the trial and increase potential recruitment. 
Institutions will use their local standard (limited to doxorubicin ± ifosfamide) and a retrospective 
propensity-based comparison on the ifosfamide addition is planned. 
Conducting clinical trials in rare cancers remains difficult. In addition to severe design restrictions due 
to the need to keep sample sizes low, successful collaboration among various parties is required and 
often compromises due to practical limitations or lack of funding are common place. Success is rarely 
guaranteed as demonstrated by the prematurely closure of the GOG-0277/IRCI 001 trial (A phase III 
randomised trial of gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-
limited, high-grade uterine leiomyosarcoma; EudraCT 2012-002852-17; NCT01533207; Ref 63). 
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Figure 2. Recruitment and randomizations rate  
 
  
  
APPENDICES. 
Appendix A: Regimens and doses for doxorubicin +/- ifosfamide 
Single agent: 
x Doxorubicin 
x Doxorubicin (Adriamycin) 75 mg/m2 iv bolus q3w 
Santoro, A et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment 
of advanced soft tissue sarcomas: A randomized study of the European Organisation for Research and 
Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13:1537  
N.B.: Doxorubicin 50-60 mg/m2 iv bolus q3w OR Doxorubicin 20-25 mg/m2 iv bolus weekly x 3 for each 
cycle up to 6 cycles can be used alternatively, according to the discretion of the responsible clinician 
(Principal Investigator [PI]) at the site, depending on the individual patient. 
Combination chemotherapy: 
x Regimen 1 
Doxorubicin (Adriamycin) 50 mg/m2 iv bolus d1 and Ifosfamide 5 g/m2 iv , d1 with Mesna before, 
during and after in appropriate doses, q3 weeks. Growth factor support to be used at the 
discretion of the PI.  
Le Cesne, A et al. Randomized phase III study comparing conventional-dose doxorubicin plus 
ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-
macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European 
Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 
2000; 18:2676  
x Regimen 2 
Doxorubicin (Adriamycin) 20 mg/m2 x 3, d1-3 (total dose 60 mg/m2), or by continuous IV infusion 
as per the original protocol and Ifosfamide 1.5 g/m2/d iv x 4, d1-4 (total dose 6 g/m2), with Mesna 
before, during and after in appropriate doses, q3 weeks. Growth factor support is advised, the 
type is at the discretion of the PI and institution.  
Worden, FP et al. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and 
granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin 
and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005; 23:105. 
N.B.: Other G-CSF are also permitted according to local practice 
 
Appendix B: FIGO staging for uterine sarcomas (2009) 
Stage Definition 
Leiomyosarcomas and endometrial stromal sarcomasa 
I Tumor limited to uterus 
 IA Less than or equal to 5 cm 
 IB More than 5 cm 
Stage Definition 
II Tumor extends beyond the uterus, within the pelvis 
 IIA Adnexal involvement 
 IIB Involvement of other pelvic tissues 
III Tumor invades abdominal tissues (not just protruding into the abdomen) 
 IIIA One site 
 IIIB More than one site 
 IIIC Metastasis to pelvic and/or para-aortic lymph nodes 
IV 
 
 IVA Tumor invades bladder and/or rectum 
 IVB Distant metastasis 
Adenosarcomas 
I Tumor limited to uterus 
 IA Tumor limited to endometrium/endocervix with no myometrial invasion 
 IB Less than or equal to half myometrial invasion 
 IC More than half myometrial invasion 
II Tumor extends beyond the uterus, within the pelvis 
 IIA Adnexal involvement 
 IIB Tumor extends to extrauterine pelvic tissue 
III Tumor invades abdominal tissues (not just protruding into the abdomen). 
 IIIA One site 
 IIIB More than one site 
 IIIC Metastasis to pelvic and/or para-aortic lymph nodes 
IV 
 
 IVA Tumor invades bladder and/or rectum 
 IVB Distant metastasis 
a Simultaneous endometrial stromal sarcomas of the uterine corpus and ovary/pelvis in association 
with ovarian/pelvic endometriosis should be classified as independent primary tumors 
 
